X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ABBOTT INDIA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ABBOTT INDIA FRESENIUS KABI ONCO./
ABBOTT INDIA
 
P/E (TTM) x 22.1 37.9 58.4% View Chart
P/BV x 3.1 11.0 28.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FRESENIUS KABI ONCO.   ABBOTT INDIA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA
Mar-17
FRESENIUS KABI ONCO./
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1765,190 3.4%   
Low Rs794,351 1.8%   
Sales per share (Unadj.) Rs37.71,382.9 2.7%  
Earnings per share (Unadj.) Rs5.1130.2 3.9%  
Cash flow per share (Unadj.) Rs6.7137.9 4.9%  
Dividends per share (Unadj.) Rs040.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5652.7 6.5%  
Shares outstanding (eoy) m158.2321.25 744.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 97.9%   
Avg P/E ratio x25.036.6 68.2%  
P/CF ratio (eoy) x18.934.6 54.7%  
Price / Book Value ratio x3.07.3 40.9%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m20,135101,373 19.9%   
No. of employees `0001.23.1 37.4%   
Total wages/salary Rs m7033,453 20.4%   
Avg. sales/employee Rs Th5,176.29,531.9 54.3%   
Avg. wages/employee Rs Th610.41,119.9 54.5%   
Avg. net profit/employee Rs Th699.6897.3 78.0%   
INCOME DATA
Net Sales Rs m5,96329,387 20.3%  
Other income Rs m18576 3.1%   
Total revenues Rs m5,98129,963 20.0%   
Gross profit Rs m1,4303,973 36.0%  
Depreciation Rs m258164 157.0%   
Interest Rs m-2620 -127.5%   
Profit before tax Rs m1,2164,365 27.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,598 21.4%   
Profit after tax Rs m8062,767 29.1%  
Gross profit margin %24.013.5 177.4%  
Effective tax rate %28.136.6 76.8%   
Net profit margin %13.59.4 143.6%  
BALANCE SHEET DATA
Current assets Rs m5,10218,906 27.0%   
Current liabilities Rs m2,3856,297 37.9%   
Net working cap to sales %45.642.9 106.2%  
Current ratio x2.13.0 71.2%  
Inventory Days Days15062 241.3%  
Debtors Days Days11322 523.5%  
Net fixed assets Rs m5,1481,159 444.3%   
Share capital Rs m158213 74.4%   
"Free" reserves Rs m6,55613,657 48.0%   
Net worth Rs m6,73213,869 48.5%   
Long term debt Rs m9520-   
Total assets Rs m10,38820,638 50.3%  
Interest coverage x-45.8215.0 -21.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.4 40.3%   
Return on assets %7.513.5 55.6%  
Return on equity %12.019.9 60.0%  
Return on capital %14.631.6 46.2%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2980-   
Fx outflow Rs m1,7720-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,2743,072 41.5%  
From Investments Rs m-1,204-1,554 77.5%  
From Financial Activity Rs m-196-898 21.8%  
Net Cashflow Rs m-126621 -20.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 9.6 0.1 9,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   42,599 18,270 233.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

ABBOTT INDIA surges by 5%; BSE HEALTHCARE Index Up 0.5%

Jun 20, 2018 | Updated on Jun 20, 2018

ABBOTT INDIA share price has surged by 5% and its Current Market Price is Rs 7,284. The BSE HEALTHCARE is up by 0.49%. The top gainers in the BSE HEALTHCARE Index is ABBOTT INDIA (up 5.08%). The top losers are WOCKHARDT LTD. (down 0.04%) and SYNGENE INTERNATIONAL (down 0.15%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS